$28.56
+0.25 (+0.88%)
Open$28.74
Previous Close$28.31
Day High$28.75
Day Low$27.64
52W High$43.66
52W Low$15.93
Volume—
Avg Volume451.6K
Market Cap573.13M
P/E Ratio—
EPS$-3.16
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
-12.0% upside
Current
$28.56
$28.56
Target
$25.14
$25.14
$17.03
$25.14 avg
$37.02
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 808.7K | 64.19M | 65.56M |
| Net Income | -65,643,442 | 8.40M | 8.13M |
| Profit Margin | -8,123.7% | 13.1% | 12.4% |
| EBITDA | -70,237,992 | 15.55M | 13.35M |
| Free Cash Flow | — | 10.13M | 9.92M |
| Rev Growth | — | +4.7% | +24.1% |
| Debt/Equity | 0.00 | 0.89 | 0.79 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |